Simulations Plus has renewed its research collaboration agreements with the U.S. FDA and NIEHS, continuing efforts on computational mechanistic modeling for drug safety evaluation. The extensions will support development of in silico models to predict pharmacokinetics, toxicity thresholds and environmental health risks, though specific timelines and funding levels remain undisclosed.